PURPOSE: As the premalignant lesion of human esophageal adenocarcinoma (EAC), Barrett's esophagus (BE) is characterized by intestinal metaplasia in the normal esophagus (NE). Gene expression profiling with microarray and serial analysis of gene expression (SAGE) may help us understand the potential molecular mechanism of human BE. METHODS: We analyzed three microarray datasets (two cDNA arrays and one oligonucleotide array) and one SAGE dataset with statistical tools, significance analysis of microarrays (SAM) and SAGE(Poisson), to identify individual genes differentially expressed in BE. Gene set enrichment analysis (GSEA) was used to identify a priori defined sets of genes that were differentially expressed. These gene sets were grouped according to either certain signaling pathways (GSEA curated), or the presence of consensus binding sequences of known transcription factors (GSEA motif). Immunohistochemical staining (IHC) was used to validate differential gene expression. RESULTS: Both SAM and SAGE(Poisson) identified 68 differentially expressed genes (55 BE genes and 13 NE genes) with an arbitrary cutoff ratio (> or =4-fold). With IHC on matched pairs of NE and BE tissues from 6 patients, these genes were grouped into 6 categories: category I (25 genes only expressed in BE), category II (5 genes only expressed in NE), category III (8 genes expressed more in BE than in NE), and category IV (2 genes expressed more in NE than in BE). Differential expression of the remaining genes was not confirmed by IHC either due to false discovery (category V), or lack of proper antibodies (category VI). Besides individual genes, the TGFbeta pathway and several transcription factors (CDX2, HNF1, and HNF4) were identified by GSEA as enriched pathways and motifs in BE. Apart from 9 target genes known to be up-regulated in BE, IHC staining confirmed up-regulation of 19 additional CDX1 and CDX2 target genes in BE. CONCLUSION: Our data suggested an important role of CDX1 and CDX2 in the development of BE. The IHC-confirmed gene list will lead to future studies on the molecular mechanism of BE.
PURPOSE: As the premalignant lesion of humanesophageal adenocarcinoma (EAC), Barrett's esophagus (BE) is characterized by intestinal metaplasia in the normal esophagus (NE). Gene expression profiling with microarray and serial analysis of gene expression (SAGE) may help us understand the potential molecular mechanism of human BE. METHODS: We analyzed three microarray datasets (two cDNA arrays and one oligonucleotide array) and one SAGE dataset with statistical tools, significance analysis of microarrays (SAM) and SAGE(Poisson), to identify individual genes differentially expressed in BE. Gene set enrichment analysis (GSEA) was used to identify a priori defined sets of genes that were differentially expressed. These gene sets were grouped according to either certain signaling pathways (GSEA curated), or the presence of consensus binding sequences of known transcription factors (GSEA motif). Immunohistochemical staining (IHC) was used to validate differential gene expression. RESULTS: Both SAM and SAGE(Poisson) identified 68 differentially expressed genes (55 BE genes and 13 NE genes) with an arbitrary cutoff ratio (> or =4-fold). With IHC on matched pairs of NE and BE tissues from 6 patients, these genes were grouped into 6 categories: category I (25 genes only expressed in BE), category II (5 genes only expressed in NE), category III (8 genes expressed more in BE than in NE), and category IV (2 genes expressed more in NE than in BE). Differential expression of the remaining genes was not confirmed by IHC either due to false discovery (category V), or lack of proper antibodies (category VI). Besides individual genes, the TGFbeta pathway and several transcription factors (CDX2, HNF1, and HNF4) were identified by GSEA as enriched pathways and motifs in BE. Apart from 9 target genes known to be up-regulated in BE, IHC staining confirmed up-regulation of 19 additional CDX1 and CDX2 target genes in BE. CONCLUSION: Our data suggested an important role of CDX1 and CDX2 in the development of BE. The IHC-confirmed gene list will lead to future studies on the molecular mechanism of BE.
Authors: Elizabeth Pohler; Ashley L Craig; James Cotton; Laura Lawrie; John F Dillon; Pete Ross; Neil Kernohan; Ted R Hupp Journal: Mol Cell Proteomics Date: 2004-02-15 Impact factor: 5.911
Authors: Rebecca A Ihrie; Michelle R Marques; Bichchau T Nguyen; Jennifer S Horner; Cristian Papazoglu; Roderick T Bronson; Alea A Mills; Laura D Attardi Journal: Cell Date: 2005-03-25 Impact factor: 41.582
Authors: James Helm; Steven A Enkemann; Domenico Coppola; James S Barthel; Scott T Kelley; Timothy J Yeatman Journal: Clin Cancer Res Date: 2005-04-01 Impact factor: 12.531
Authors: Erik T Kimchi; Mitchell C Posner; James O Park; Thomas E Darga; Masha Kocherginsky; Theodore Karrison; John Hart; Kerrington D Smith; James J Mezhir; Ralph R Weichselbaum; Nikolai N Khodarev Journal: Cancer Res Date: 2005-04-15 Impact factor: 12.701
Authors: Michael Mitas; Jonas S Almeida; Kaidi Mikhitarian; William E Gillanders; David N Lewin; Demetri D Spyropoulos; Loretta Hoover; Amanda Graham; Tammy Glenn; Peter King; David J Cole; Robert Hawes; Carolyn E Reed; Brenda J Hoffman Journal: Clin Cancer Res Date: 2005-03-15 Impact factor: 12.531
Authors: Xia Wang; Hong Ouyang; Yusuke Yamamoto; Pooja Ashok Kumar; Tay Seok Wei; Rania Dagher; Matthew Vincent; Xin Lu; Andrew M Bellizzi; Khek Yu Ho; Christopher P Crum; Wa Xian; Frank McKeon Journal: Cell Date: 2011-06-24 Impact factor: 41.582
Authors: Shaohua Ma; Chorlada Paiboonrungruan; Tiansheng Yan; Kevin P Williams; M Ben Major; Xiaoxin Luke Chen Journal: Ann N Y Acad Sci Date: 2018-05-11 Impact factor: 5.691
Authors: David H Wang; Anjana Tiwari; Monica E Kim; Nicholas J Clemons; Nanda L Regmi; William A Hodges; David M Berman; Elizabeth A Montgomery; D Neil Watkins; Xi Zhang; Qiuyang Zhang; Chunfa Jie; Stuart J Spechler; Rhonda F Souza Journal: J Clin Invest Date: 2014-08-01 Impact factor: 14.808